Cargando…
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
Several oncogenic mechanisms have been identified for MET, including MET amplification, fusions, mutations in the tyrosine kinase domain and exon 14 skipping alterations. MET exon 14 mutations are found in about 3–5% of non-small-cell lung cancers. Dysregulation of the MET receptor leads to cell pro...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioExcel Publishing Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255265/ https://www.ncbi.nlm.nih.gov/pubmed/35855460 http://dx.doi.org/10.7573/dic.2022-2-2 |